Full Press Release Details
Blue Water Vaccines Announces Appointment
of Retired Deloitte Consulting Senior Managing Director Simon Tarsh to Board of Directors
August 22, 2022 at 2:00 PM EDT
Aug. 22, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or "the Company"),
a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced the
appointment of Simon Tarsh, seasoned financial consultant with experience in the life science industry, to its board of directors at BWV's
brings over 40 years of experience in the financial industry to the Company, most recently serving global clients as a Senior Managing
Director in the Finance and Enterprise Performance Practice at Deloitte Consulting since 2007. He led a growing global practice focused
on Operational Transformation, including supporting Carve Out transactions, joint ventures and hybrid structures, both in the US and in
international locations, such as India, China, Eastern Europe and Latin America. Throughout his career, he has supported high growth companies
with their financial operations as they globalized, advising them on their expansion while balancing growth with appropriate controls.
are honored to welcome Mr. Tarsh to the Blue Water Vaccines Board of Directors following his appointment at the BWV annual meeting,"
said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines. "His distinguished career in accounting and
financial consulting across many sectors, including the life science industry, will be invaluable to our operations as we continue to
advance our vaccine pipeline and develop novel vaccine candidates."
received a Bachelor of Science undergraduate degree in Business and Administration from the University of Salford, Manchester, UK in 1981,
and an MBA from City University Business School, London, UK in 1988. He is a Fellow of the Chartered Institute of Management Accountants
(1984), which is considered as a CPA equivalent.
Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges
globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford,
Cincinnati Children's Hospital Medical Center, and St. Jude Children's Hospital. The company is developing a universal flu vaccine that
will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like
particle (VLP) vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including norovirus/rotavirus
and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate,
designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children. For more
information, visit www.bluewatervaccines.com.
in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast,"
"estimate," "expect," and "intend," among others. These forward-looking statements are based on BWV's
current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the
development of BWV's vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations;
delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our
product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government
or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition.
As with any vaccine under development, there are significant risks in the development, regulatory approval and commercialization of new
products. BWV does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors
set forth in BWV's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange
Commission (the "SEC") on March 31, 2022, Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the
SEC on August 15, 2022 and periodic reports filed with the SEC on or after the date thereof. All of BWV's forward-looking statements
are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the
Blue Water Media Relations
Telephone: (646) 942-5591
Contact Information:
Blue Water Investor Relations